Genetic Engineering & Biotechnology News (GEN) is the world's most widely read biotech publication. It provides the R&D community with critical information on the tools, technologies, and trends that drive the biotech industry.
Issue link: http://gen.epubxp.com/i/806913
Genetic Engineering & Biotechnology News | GENengnews.com | APRIL 15, 2017 | 23 modular Finesse control system. Finesse's TruBio ® control software and the control hardware are designed to fit the indus- try's needs for an off-the-shelf solution that enables a solid but quick validation, easy to adopt process control strategies, and the flex- ibility to swap process equipment in size or type. The DeltaV ® -based IT backbone secures the data integrity while the Finesse SmartParts enable the flexibility and control precision. As an example, the G3Lab Universal Con- troller can run Finesse's small-scale dispos- able 3 L SmartVessels, Finesse glass, or other brand's vessels. Also, the SmartRocker or even a 250 L HyPerforma SUB can be perfectly controlled by the same unit. It combines a series of SmartParts [i.e., the TruFlow master flow controller (MFC) manifold] to become a universal controller and communicates with the TruBio software. If a TruFlow unit gets replaced by one for higher flow rates, TruBio will automati- cally recognize the new number of MFCs, gas types, and flowrates. This software-supported hardware modularity improves process con- trol, product yield, and quality. GEN How did the acquisition of Finesse by Thermo Fisher in February increase your modular automation capabilities? Mr. Tillich Before Thermo Fisher acquired Finesse Solutions, we had superior products for nearly every area of the workflow such as single-use, cell culture, purification, and even Pharma analytics products. Now, Thermo Fisher is are able to provide those products to our customers in an open architecture format, and automate the process. This provides an unparalleled level of flexibility and automa- tion not previously available. GEN Briefly describe the key technologies required in today's bioproduction work- flow and how the Finesse components help tie together the entire process. Mr. Tillich The key technologies are: bio- reactors, bioprocess containers, media, filters, chromatography resins, and the skids/automation that enable their auto- mated use. Finesse provides the controllers and software for running these skids, and is developing these skids. Finesse also al- lows the data from the workflow and third-party analytics to be collected in one repository and analyzed for process optimization. Essentially, Finesse provides the bind- ing layer for the workflow process control and data management, leading to im- proved productivity in cGMP production and faster scale-up from R&D through production. Perspectives Bioprocessing When a strategic decision is made to be prepared for rapid changes in R&D or production, Thermo says modular automation is the right answer because it can provide the flexibility required for those varying circumstances. Thermo Fisher Scientific The Next Evolution For the past 75 years, Kerry has evolved with the market trends in cell culture. As our customers' needs changed we have expanded our product portfolio to encompass technologies needed to meet the evolving needs of the bio-pharma market globally. AmpliCHO CD medium is our latest evolution. AmpliCHO CD medium is a completely chemical chemically-defi ned medium that does not contain supplements. It is optimized for extended growth and enhanced recombinant protein production for CHO suspension cultures. The benefi ts of using AmpliCHO CD medium: ● Signifi cantly higher titers ● Low osmolality ● Extended viable density and cell viability ● Animal component free (ACF) ● Compatible with complex, defined, and CD supplements and feed Chemically Defi ned Medium | Supplement Systems | Defi ned Supplements | Hydrolyzed Proteins | Yeast Extracts Learn more at Sheffi eldBioScience.com Bioprocessing cell-line development or bioproduction (clone creation, RCB/DCB, MCB), without the need to change culture conditions, according to Geoffrey Holsbeek, CEO of Amplycell. Horizon is applying a disruptive busi- ness model alongside its expertise in genome editing to improve the manufac- ture of biotherapeutics, making its CHO cells available to companies of all sizes, added Terry Pizzie, head of commercial, Horizon Discovery. Before releasing its next generation of bioproduction cell lines, Horizon will eval- uate the impact of Amplycell's technology on the expression capability of its paren- tal GS-null CHO-K1 cell line. If the evalua- tion is successful, both parties anticipate a long-term relationship, with the BOOST procedure being applied as standard to future generations of cell lines. Under the terms of the agreement, Horizon will make an upfront payment to AmplyCell. Upon establishing a positive impact on the CHO cell line, AmplyCell will then be entitled to receive success- based development and commercial milestone payments and Horizon will have the nonexclusive worldwide rights to sublicense these BOOSTed CHO-K1 cell lines to third parties. AmplyCell is also eli- gible to receive tiered royalties based on the net sales of these sublicensed lines. "We are hopeful that a successful eval- uation of AmplyCell's BOOST technology will lead to incorporation of this method- ology for all future bioprocessing cell lines released by Horizon, noted Pizzie. n